Pharvaris (PHVS) Cash & Equivalents (2019 - 2026)

Pharvaris has reported Cash & Equivalents for 8 years, with the latest figure at $289.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 2.09% year-over-year to $289.1 million; the trailing twelve-month figure through Mar 2026 stood at $289.1 million (down 2.09% YoY), and the FY2025 full-year result was $329.5 million, up 8.46% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $289.1 million, down from $339.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $429.7 million in Q3 2024, with the low at $176.23 in Q2 2023.
• Historically, Cash & Equivalents has averaged $249.3 million across 5 years, with a median of $235.0 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 100.0% — and 2025, when it soared 53619744.65%.
• Pharvaris' Cash & Equivalents stood at $165.1 million in 2022, then surged by 154.94% to $420.9 million in 2023, then declined by 28.73% to $300.0 million in 2024, then rose by 13.18% to $339.5 million in 2025, then fell by 14.84% to $289.1 million in 2026.
• The last three Cash & Equivalents figures came in at $289.1 million (Q1 2026), $339.5 million (Q4 2025), and $328.2 million (Q3 2025), per Business Quant data.